Abbott Laboratories (NYSE:ABT) Stock Price Target Lowered at Royal Bank Of Canada

Abbott Laboratories (NYSE:ABT) had its target price reduced by equities researchers at Royal Bank Of Canada from $130.00 to $125.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the healthcare product maker’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 22.37% from the company’s current price.

Other equities analysts have also issued research reports about the company. Robert W. Baird raised their price objective on Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research note on Thursday. UBS Group dropped their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Citigroup increased their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. TD Cowen reduced their target price on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $117.92.

Abbott Laboratories Stock Performance

NYSE ABT traded up $1.64 during trading on Thursday, reaching $102.15. The company’s stock had a trading volume of 2,859,598 shares, compared to its average volume of 11,290,545. The firm has a 50 day moving average price of $105.47 and a 200 day moving average price of $98.28. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $132.02. The firm has a market capitalization of $176.76 billion, a price-to-earnings ratio of 33.03, a price-to-earnings-growth ratio of 1.90 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. During the same period last year, the firm earned $1.30 earnings per share. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, equities analysts anticipate that Abbott Laboratories will post 5.53 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

Large investors have recently made changes to their positions in the company. Ledyard National Bank lifted its position in shares of Abbott Laboratories by 6.4% during the third quarter. Ledyard National Bank now owns 15,237 shares of the healthcare product maker’s stock valued at $1,506,000 after purchasing an additional 913 shares in the last quarter. Culbertson A N & Co. Inc. increased its holdings in Abbott Laboratories by 0.3% during the third quarter. Culbertson A N & Co. Inc. now owns 90,195 shares of the healthcare product maker’s stock worth $8,914,000 after buying an additional 270 shares during the last quarter. NBT Bank N.A. bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth approximately $9,060,000. Root Financial Partners LLC raised its stake in shares of Abbott Laboratories by 93.7% in the third quarter. Root Financial Partners LLC now owns 7,430 shares of the healthcare product maker’s stock valued at $734,000 after buying an additional 3,594 shares during the period. Finally, Precedent Wealth Partners LLC lifted its position in shares of Abbott Laboratories by 10.7% during the 3rd quarter. Precedent Wealth Partners LLC now owns 33,354 shares of the healthcare product maker’s stock valued at $3,296,000 after buying an additional 3,234 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter performance was broadly solid: adjusted earnings were $1.42 per share, in line with consensus, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding estimates. Comparable sales increased 7%. Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Analysts remain constructive despite trimming some targets. Robert W. Baird raised its target to $123, while BTIG, JPMorgan and TD Cowen maintained buy-equivalent ratings with targets ranging from $118 to $125, implying meaningful upside from recent levels.
• Positive Sentiment: Abbott received European regulatory clearance for Cologuard Plus, expanding the potential market for its noninvasive colorectal-cancer screening test. Cologuard Plus European approval
• Neutral Sentiment: Abbott plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Pedialyte, PediaSure and Glucerna—into an independent, publicly traded company through a tax-free distribution to shareholders by the end of 2027. Management expects the transaction to give both companies more focused growth strategies, though investors must assess execution and the future value of the separated businesses. Abbott Nutrition spinoff announcement
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing diabetes-related pricing pressure and weakness in electrophysiology and other medical-device areas. That guidance reduction overshadowed the quarterly revenue performance and caused the stock to decrease after the announcement. Reuters Abbott outlook report
• Negative Sentiment: Although adjusted EPS matched the broader consensus, some services reported a modest miss against the higher Zacks estimate of $1.43. Combined with the lower sales outlook and uncertainty around the spinoff, this has increased near-term investor caution.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.